Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume205.10K
Average Volume (3M)65.17K
Market Cap
C$23.11M
Enterprise ValueC$25.61
Total Cash (Recent Filing)C$5.21M
Total Debt (Recent Filing)C$338.40K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding308,182,160
10 Day Avg. Volume35,116
30 Day Avg. Volume65,172
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing SupportThe private placement provides near-term funding for working capital and research activities, helping support operations while the company advances its pipeline. Although financing is not operating revenue, it can extend execution capacity and reduce immediate pressure to fund development solely through ongoing capital raises.
Equity StabilizationThe move from negative to positive equity represents a meaningful improvement in balance-sheet structure and provides a stronger capital base than the company had in earlier periods. This stabilization may improve financial resilience, even though subsequent asset declines and losses show that the improvement remains fragile.
Pipeline AdvancementProgressing S-100 toward human clinical trials creates a defined development milestone and gives the company a tangible path for converting research activity into a potential future product opportunity. Clinical advancement could strengthen partnering or commercialization prospects if development continues successfully.
Bears Say
No Current RevenueZero current revenue indicates that the business is not presently demonstrating commercial monetization from its activities. The sharp break from earlier modest revenue reduces visibility into operating traction and means future development must be funded without support from an established recurring revenue base.
Persistent Cash BurnSustained negative operating and free cash flow shows that the company cannot currently self-fund its operations and development programs. Worsening burn increases dependence on external financing, which can constrain strategic flexibility and expose the business to repeated funding requirements over the coming quarters.
Widening Operating LossesThe widening loss profile indicates that expenses remain materially ahead of any operating income, leaving no demonstrated path to near-term profitability in the reported results. Continued losses can consume the strengthened equity base and require additional financing before pipeline investments generate commercial returns.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$23.11M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Dec 18, 2026 which is in 89 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Jul 30, 2026. The company reported -C$0.002 earnings per share for the quarter.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 308,182,160 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.002 in its last earnings report. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―